Navigation Links
YM BioSciences reports fiscal year end 2010 operational and financial results
Date:9/23/2010

MISSISSAUGA, ON, Sept. 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today reported operational and financial results for its fiscal year end, ended June 30, 2010.

"This has been a transformative year for YM. Our most notable development was the merger of the public Australian company, Cytopia, into YM BioSciences, completed in January, from which we gained two important clinical stage drug candidates, CYT387 and CYT997, as well as a library of more than 4,000 novel compounds in addition to the ongoing advancement of nimotuzumab by us and our four licensees," said David Allan, Chairman and CEO of YM BioSciences. "Work on CYT387, a potent, orally-administered JAK1/JAK2 inhibitor, has resulted in favorable biological activity and safety data observed in recent months and as such have announced the expansion of our current Phase I/II program in myelofibrosis initiated at Mayo Clinic from 60 to up to 120 patients and the inclusion of up to six centers in the United States, Canada and Australia. We also look forward to the American Society of Hematology (ASH) meeting in Orlando, Florida, in early December 2010, where detailed safety and preliminary activity data for CYT387 are expected to be presented."

"During the fiscal period we raised an additional $20 million in two financings that brought in a number of highly regarded life-sciences investors as shareholders and we also recently announced the appointment of Dr. Nick Glover as President and COO of YM. By strengthening both our balance sheet and leadership team we have positioned YM to seize the significant new opportunities that our expanded pipeline presents," added Mr. Allan.

Highlights from Fiscal 2010: CYT387 - Pivotal preclinical efficacy data for CYT387 in myeloproliferative neoplasms were published in Blood, the Journal of the American Society of Hematology (Blood, 24 June 2010, Vol. 115, # 25, pp. 5232-5240). - Subsequent to quarter end, Mayo Clinic conclu
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
2. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
3. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Ambit Biosciences Announces Transition in Company Leadership
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Calithera Biosciences Closes $40 Million in Series A Financing
10. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
11. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... -- After announcing last April a method for ... cylinders only a few atoms thick, a Duke ... process to create exclusively semiconducting versions of these ... way for manufacturing reliable electronic nanocircuits at the ...
... , ... Englewood, CO (PRWEB) January 21, 2009 -- ... (OTJ), has announced new solutions for human resource and recruitment professionals ... geographically localized markets. , , , , ,OTJ currently powers online ...
... in Diabetes Drug TherapyHARTFORD, Conn., Jan. 21 ... of certain genes in vascular and energy pathways ... retention) in patients taking the thiazolidinedione (TZD) drugs ... from Joslin Diabetes Center Affiliate at The Hospital ...
Cached Biology Technology:Semiconducting nanotubes produced in quantity at Duke 2Semiconducting nanotubes produced in quantity at Duke 3onTargetjobs Offers Employers New Recruitment Solutions to Reach Local Career Candidates 2Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study 2
(Date:4/18/2014)... contraceptive pills in Peru found that 28 percent ... quality or falsified. Many pills released the active ... ingredient. One batch had no active ingredient at ... researchers at the Georgia Institute of Technology developed ... assess suspected counterfeit drugs and then characterize their ...
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... 17 In the most densely forested and most ... two centuries of human needs, values and practices. Disturbances ... forests for agriculture and development, have set the stage ... Forest Service study reports. , The report Five ... management needs in the Northern United States ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... estrogen receptors are more difficult to treat than ... Meeting 2013 demonstrates an investigational drug, Paragazole, that ... and that increases the sensitivity of these cells ... do is use triple-negative breast cancer models to ...
... identified four genes newly associated with severe childhood obesity. ... variations in severely obese children. The team found ... help to maintain protein receptors known to be involved ... targets for the development of new drugs against obesity. ...
... biologist at the Florida State University College of Medicine ... closer to understanding how life first emerged on Earth ... team produced data supporting the idea that 10 amino ... years ago were capable of forming foldable proteins in ...
Cached Biology News:Finding genes for childhood obesity 2Researcher offers clues on the origins of life 2Researcher offers clues on the origins of life 3
...
Contains L-glutamine...
...
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
Biology Products: